Redeye provides commentary on NextCell following recent newsflow including raising SEK36.
Redeye comments on this morning’s news that Kancera has received positive feedback on the planned cl...
With its updated core business strategy, Enersense is extending its focus from construction to maint...
Redeye provides a brief comment on today’s news regarding Scibase's first order in Italy.
Redeye is positive about SynAct’s new directed issue and loan agreement with Hunter Capital, both of...
Redeye comments on Faron’s ASCO 2025 presentation of full phase II BEXMAB data in high-risk MDS.
Redeye comments on OncoZenge’s engagement of LINK Medical to conduct a feasibility study ahead of it...
Analysguiden ser potentialen i Studentbostäder i Norden och målet om en belåningsgrad om max 60% til...
Redeye leaves a short comment on the final outcome of Iconovo’s fully guaranteed rights issue.
Directed share issue and new financial targets Sales SEK 400m by '28e and EBIT/cash flow positive b...
Enersense released new financial targets as a pure service company on 4 June.
Redeye updates its outlook on Genovis following a Q1 report coming in slightly above our estimates a...
Redeye return with a research update following BioArctic's Q1 report and capital markets day.
Analysguiden inleder bevakning av Case Group AB som haft en stark tillväxt under 2024–2025 med ökat ...
Redeye leaves its initial comments on Integrum’s Q4 report.
Redeye comments on Jumpgate’s announcement regarding the approval of SEK13.
Q1 figures above ABGSCe Minor underlying changes, applying our latest oil market view Fair value ran...
Creditas, som utgör cirka 40% av VEFs investeringsportfölj, går in i en ny tillväxtfas och presenter...
Lipigon räknar fortsatt med att sista patient i bolagets fas 2-studie ska påbörja behandling före ha...
Proport Invest är ett svenskt, onoterat investeringsbolag som fokuserar på entreprenörsledda bolag m...
